US 11,814,686 B2
Method for screening and treating a subject for a cancer
Alain Thierry, Montpellier (FR); and Cynthia Sanchez, Montpellier (FR)
Assigned to INSTITUT NATIONAL DE LA SANTÉDE LA RECHERCHE MÉDICALE, Paris (FR); UNIVERSITÉ de MONTPELLIER, Montpellier (FR); and INSTITUT RéGIONAL DU CANCER DE MONTPELLIER, Montpellier (FR)
Appl. No. 16/770,351
Filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Paris (FR); Université de Montpellier, Montpellier (FR); and Institut Régional du Cancer de Montpellier, Montpellier (FR)
PCT Filed Dec. 6, 2018, PCT No. PCT/EP2018/083851
§ 371(c)(1), (2) Date Jun. 5, 2020,
PCT Pub. No. WO2019/110750, PCT Pub. Date Jun. 13, 2019.
Claims priority of application No. 17306721 (EP), filed on Dec. 7, 2017.
Prior Publication US 2021/0172019 A1, Jun. 10, 2021
Int. Cl. C12Q 1/6886 (2018.01); C12Q 1/6806 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 1/6806 (2013.01); C12Q 2600/112 (2013.01)] 3 Claims
 
1. A method for treating cancer in a subject in need thereof, comprising the steps of:
i) extracting cell free DNA from a sample obtained from a subject;
ii) denaturating the cell free DNA to obtain single stranded DNA fragments;
iii) determining the levels of single stranded DNA fragments having a length ranging from 98 to 158 nucleotides and from 168-218 nucleotides; and
iv) administering one or more cancer treatments to a subject identified as having
a higher level than a predetermined reference value of at least one single stranded DNA fragment ranging from 98 to 158 nucleotides, and
a lower level than a predetermined reference value of at least one single stranded DNA fragment having a length ranging from 168 to 218 nucleotides;
wherein the one or more cancer treatments are selected from the group consisting of radiotherapy, chemotherapy, and immunotherapy.